コメント (10)
トラックバックは利用できません。
Diflucan’s long half-life enables once-daily dosing, improving adherence.
“Fluconazole-refractory” candidiasis is a specific clinical entity in advanced AIDS.
The mechanism is distinct from echinocandins, providing a valuable alternative class.
Diflucan has a post-antimicrobial effect against some Candida species.
Diflucan can be a cost-effective alternative to more expensive antifungals when susceptibility is confirmed.
Diflucan is often the first systemic antifungal agents that clinicians learn to use.
Development of the IV formulation expanded use to critically ill and unable-to-swallow patients.
Therapeutic drug monitoring is not routinely required but can be useful in specific scenarios.
Hepatic metabolism becomes more significant in patients with end-stage renal disease.
In vitro synergy has been studied in combination with other agents like flucytosine.
Diflucan’s long half-life enables once-daily dosing, improving adherence.
“Fluconazole-refractory” candidiasis is a specific clinical entity in advanced AIDS.
The mechanism is distinct from echinocandins, providing a valuable alternative class.
Diflucan has a post-antimicrobial effect against some Candida species.
Diflucan can be a cost-effective alternative to more expensive antifungals when susceptibility is confirmed.
Diflucan is often the first systemic antifungal agents that clinicians learn to use.
Development of the IV formulation expanded use to critically ill and unable-to-swallow patients.
Therapeutic drug monitoring is not routinely required but can be useful in specific scenarios.
Hepatic metabolism becomes more significant in patients with end-stage renal disease.
In vitro synergy has been studied in combination with other agents like flucytosine.